Streetbeat News

Analyst Ratings

INVH

JP Morgan analyst Anthony Paolone maintains a Neutral rating on Invitation Homes (NYSE:INVH) and raises the price target from $34 to $35.

Portfolio Pulse from richadhand@benzinga.com

May 26, 2023 | 2:07 pm

AMH

JP Morgan analyst Anthony Paolone maintains a Neutral rating on American Homes 4 Rent (NYSE:AMH) and raises the price target from $34 to $35.

Portfolio Pulse from richadhand@benzinga.com

May 26, 2023 | 2:05 pm

GH

In the last quarter, Guardant Health (NASDAQ:GH) received 1 bullish, 3 somewhat bullish, and 2 indifferent analyst ratings. The average 12-month price target for the company is $48.17, down 22.06% from the previous average of $61.80.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 2:04 pm

LULU

In the last quarter, Lululemon Athletica (NASDAQ:LULU) received 5 bullish, 15 somewhat bullish, 2 indifferent, and 1 bearish rating from analysts. The average 12-month price target for LULU is $419.65, with a high of $525.00 and a low of $257.00, increasing by 3.74% over the past month.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 2:03 pm

ALLO

In the last quarter, Allogene Therapeutics (NASDAQ:ALLO) received 8 bullish, 5 somewhat bullish, and 3 indifferent analyst ratings. The company's average 12-month price target is $19.22, down 27.8% from the previous average of $26.62.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 2:03 pm

CLS

In the last 3 months, 4 analysts have offered 12-month price targets for Celestica (NYSE:CLS), with an average price target of $14.38, a decrease of 5.7% from the previous average of $15.25. The ratings include 1 somewhat bullish and 3 indifferent.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 2:03 pm

ABC

In the last 3 months, 11 analysts have provided 12-month price targets for AmerisourceBergen (NYSE:ABC), with an average price target of $191.36. The average price target has increased by 3.86% over the past month.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 2:01 pm

BTAI

Over the past 3 months, 8 analysts have published their opinion on BioXcel Therapeutics (NASDAQ:BTAI) stock, with 6 bullish and 2 indifferent ratings. The average 12-month price target is $51.25, with a high of $79.00 and a low of $22.00. The average price target has increased by 19.19% over the past month.

Portfolio Pulse from Benzinga Insights

May 26, 2023 | 2:01 pm

CGEN

EF Hutton analyst Tony Butler reiterates a Buy rating on Compugen (NASDAQ:CGEN) and maintains a $13 price target.

Portfolio Pulse from richadhand@benzinga.com

May 26, 2023 | 1:56 pm